ERYTECH to stop further plans to pursue a BLA submission seeking an approval for Graspa® in hypersensitive ALL
Evaluation of strategic partnering options ongoing
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug Administration (FDA).
https://finance.yahoo.com/news/erytech-provides-regulatory-200500726.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.